Silymarin loaded liposomes for hepatic targeting: in vitro evaluation and HepG2 drug uptake.

[1]  Tao Yang,et al.  Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC , 2013, Drug development and industrial pharmacy.

[2]  Olli Ikkala,et al.  Nanofibrillar cellulose hydrogel promotes three-dimensional liver cell culture. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[3]  U. Krishnan,et al.  Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. , 2012, International journal of pharmaceutics.

[4]  Xun Sun,et al.  The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. , 2012, Fitoterapia.

[5]  M. Khan,et al.  A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. , 2012, International journal of pharmaceutics.

[6]  Jin-Seok Kim,et al.  In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[7]  V. C. Malshe,et al.  Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting. , 2010, International journal of pharmaceutics.

[8]  K. Hsu,et al.  Corrigendum to “The feasibility of antihypertensive oligopeptides encapsulated in liposomes prepared with phytosterols-b-sitosterol or stigmasterol” [Food Res. Int. 43 (2010) 133–139] , 2010 .

[9]  U. Bhardwaj,et al.  A novel USP apparatus 4 based release testing method for dispersed systems. , 2010, International journal of pharmaceutics.

[10]  W. Lu,et al.  Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. , 2008, International journal of pharmaceutics.

[11]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[12]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[13]  Javed Ali,et al.  Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches , 2007 .

[14]  R. Dikshit.  Postgraduate education in medical pharmacology , 2007 .

[15]  Dae-Duk Kim,et al.  Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. , 2007, International journal of pharmaceutics.

[16]  T. Nagai,et al.  Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  E. Mahmoud,et al.  Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. , 2006, International journal of pharmaceutics.

[18]  R. Dannenfelser,et al.  In vitro hemolysis: guidance for the pharmaceutical scientist. , 2006, Journal of pharmaceutical sciences.

[19]  J. Zhang,et al.  HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38. , 2006, Journal of pharmaceutical and biomedical analysis.

[20]  E. Mahmoud,et al.  Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. , 2006, International journal of pharmaceutics.

[21]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[22]  Mark E. Davis,et al.  A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. , 2005, Bioconjugate chemistry.

[23]  T. Nagai,et al.  Characteristics and Biodistribution of Soybean Sterylglucoside and Polyethylene Glycol-Modified Cationic Liposomes and Their Complexes with Antisense Oligodeoxynucleotide , 2005, Drug Delivery.

[24]  A. Tava,et al.  Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows. , 2004, Journal of dairy science.

[25]  Moganavelli Singh,et al.  Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[26]  R. Ševčík,et al.  Analysis of the active components of silymarin. , 2003, Journal of chromatography. A.

[27]  J. Kamps,et al.  The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. , 2003, Biochimica et biophysica acta.

[28]  T. Nagai,et al.  Liver targeting liposomes containing beta-sitosterol glucoside with regard to penetration-enhancing effect on HepG2 cells. , 2002, Biological & pharmaceutical bulletin.

[29]  Y. Park.  Tumor-Directed Targeting of Liposomes , 2002, Bioscience reports.

[30]  A. Riva,et al.  Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. , 2002, Life sciences.

[31]  T. Nagai,et al.  Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Y. Maitani,et al.  Liver-targeted gene transfer into a human hepatoblastoma cell line and in vivo by sterylglucoside-containing cationic liposomes , 2001, Gene Therapy.

[33]  S. Antimisiaris,et al.  Characterization, Stability and In - Vivo Distribution of Asialofetuin Glycopeptide Incorporating DSPC/CHOL Liposomes Prepared by Mild Cholate Incubation , 2001, Journal of drug targeting.

[34]  M. C. Annesini,et al.  Kinetics of surfactant-induced release from liposomes: A time-dependent permeability model , 2000 .

[35]  Koning,et al.  Immunoliposomes for the targeted delivery of antitumor drugs. , 1999, Advanced drug delivery reviews.

[36]  S. Luper,et al.  A review of plants used in the treatment of liver disease: part 1. , 1998, Alternative medicine review : a journal of clinical therapeutic.

[37]  T. Nagai,et al.  Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mouse models. , 1998, Biological & pharmaceutical bulletin.

[38]  Mitsuru Hashida,et al.  Development and Pharmacokinetics of Galactosylated Poly-L-Glutamic Acid as a Biodegradable Carrier for Liver-Specific Drug Delivery , 1996, Pharmaceutical Research.

[39]  G. Poli,et al.  Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. , 1995, Biochemical Pharmacology.

[40]  K. Maruyama,et al.  Enhanced Delivery and Antitumor Activity of Doxorubicin Using Long-Circulating Thermosensitive Liposomes Containing Amphipathic Polyethylene Glycol in Combination with Local Hyperthermia , 1994, Pharmaceutical Research.

[41]  R. Lewis,et al.  Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. , 1993, Biochemistry.

[42]  G. Poli,et al.  Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. , 1992, Biochemical pharmacology.

[43]  K. Koike,et al.  Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-gamma by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. , 1991, Biochemical and biophysical research communications.

[44]  E. Bosone,et al.  Inclusion complexes of Silybinin, their preparation pharmaceutical compositions containing them , 1990 .

[45]  T. Allen,et al.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.

[46]  P. Dasgupta,et al.  Receptor-mediated uptake of asialoganglioside liposomes: sub-cellular distribution of the liposomal marker in isolated liver cell types. , 1985, Biochemistry international.

[47]  A. Valenzuela,et al.  Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine. , 1985, Biochemical and biophysical research communications.

[48]  G. Scherphof,et al.  Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo. , 1983, Biochimica et biophysica acta.

[49]  E. Oldfield,et al.  Dynamics of lipids in membranes: Heterogeneity and the role of cholesterol , 1972, FEBS letters.

[50]  T. Higuchi.  MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.

[51]  Ho-Suk Choi,et al.  Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-acrylamide): drug release behavior and stability in the presence of serum. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[52]  R. Müller,et al.  Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908 , 1993 .

[53]  R. New,et al.  Liposomes : a practical approach , 1990 .

[54]  Anddemetrios Papahadjopoulos.  Procedure forpreparation ofliposomes withlarge internal aqueous spaceandhighcapture byreverse-phase evaporation , 1978 .

[55]  E. Hagemann,et al.  Rat and mouse. , 1960 .

[56]  The Inhibitory Effect , 2022 .